https://orcid.org/0000-0001-7305-9271
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The aim of this study was to evaluate the association between axitinib, sunitinib and temsirolimus toxicities and patient survival in metastatic renal cell cancer patients. Overall survival (OS) and progression-free survival (PFS) of metastatic renal cell cancer patients from the prospective multicenter STAR-TOR study were assessed using multivariable Cox models. A total of 1195 patients were included (n=149 axitinib; n=546 sunitinib; n=500 temsirolimus). The following toxicities significantly predicted outcomes: hand–foot skin reaction (hazard ratio [HR] =0.29) for PFS with axitinib; stomatitis (HR=0.62) and pneumonitis (HR=0.23) for PFS with temsirolimus; stomatitis (HR=0.52) and thrombocytopenia (HR=0.6) for OS with temsirolimus; fatigue (HR=0.71) for PFS with sunitinib; hand–foot skin reaction (HR=0.56) and fatigue (HR=0.58) for OS with sunitinib. In conclusion, in metastatic renal cell cancer, axitinib, sunitinib and temsirolimus demonstrate specific toxicities that are protective OS/PFS predictors.
Lay abstract
This study evaluates whether treatment side effects in patients with kidney cancer treated with axitinib, sunitinib and temsirolimus influence patient survival and time to cancer growth. The data show that patients with side effects have longer survival and longer time to cancer growth across all treatments; for example, patients treated with temsirolimus who developed stomach swelling had longer survival compared with patients without stomatitis. Similar results were seen for axitinib and sunitinib. These results may help to develop better treatment strategies for treatment side effects.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/fon-2020-0900
Acknowledgments
The STAR-TOR registry was funded by Pfizer Pharma GmbH, Berlin, Germany. Data management was organized by Winicker Norimed GmbH, Nuremberg, Germany. The authors thank T Fischer for providing the respective data sets.
Financial & competing interests disclosure
M Woike is an employee of Pfizer Pharma GmbH, Berlin, Germany. J Uhlig received moderate speaker fees from Bayer AG on a topic unrelated to the study at hand. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.